JSJyotsna Suri

Jyotsna Suri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jyotsna Suri has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) trial—rationale for the selected lower steroid dose

    by The Who Action Trials Collaborators, Ebunoluwa Aderonke Adejuyigbe, Olubukola Adeponle Adesina, Salahuddin Ahmed, Shabina Ariff, Adejumoke Idowu Ayede, Rajiv Bahl, Abdullah H. Baqui, Harish Chellani, Saleha Begum Chowdhury, et al.

  • Maternal and Perinatal Outcome of Peripartum Cardiomyopathy: A Single-Center Study in a Tertiary Referral Unit of India

    by Suchandana Dasgupta, Jyotsna Suri, Rekha Bharti, Sumitra Bachani, Supriya Hazarika, Himal Singla, Sandeep Bansal

  • Role of Serum Calcium and Magnesium Estimation at 20–28 Weeks of Gestation in Prediction of Pregnancy-Induced Hypertension

    by Avya Sinha, Zeba Khanam, Anita Rani, Divya Pandey, Monika Gupta, Jyotsna Suri

    Introduction Pregnancy-induced hypertension (PIH), a major contributor to global maternal morbidity and mortality, is a disorder marked by elevated blood pressure with or without end-organ damage. It is a condition unique to pregnancy that stems from abnormal uteroplacental development, and possibly, altered mineral homeostasis. Objective To determine whether estimating serum calcium (Ca2+) and magnesium (Mg2+) levels in the late-second trimester can predict PIH later in pregnancy. Material and Methods In this prospective cohort study, 225 normotensive gravid women underwent total serum Ca2+ and Mg2+ estimations between 20 and 28 weeks of gestation and at delivery. They were followed up until 48 h after delivery for the development of PIH (preeclampsia, gestational hypertension, eclampsia). Results A total of 52 (23.11%) women developed PIH, of which 14 (6.22%) women had preeclampsia. Although mean (SD) (mg/dL) serum Ca2+ (8.79(0.38) vs. 8.78(0.38); p = 0.696) and Mg2+ (1.92(0.25) vs. 1.92(0.21); p = 0.669) levels decreased between the second trimester and delivery, levels remained consistently higher in women with PIH. The ROC-AUC of serum Mg2+ for predicting PIH and preeclampsia at 20–28 weeks of gestation was 0.577 (95%CI 0.509,0.642); p = 0.09) and 0.647 (95%CI 0.581,0.709; p = 0.041), respectively; for serum Ca2+, the values were 0.544 (95%CI 0.476,0.61; p = 0.359) and 0.558 (95%CI 0.491,0.62; p = 0.46), respectively. At a serum Mg2+(mg/dL) cut-off value of > 1.9, the sensitivity of predicting preeclampsia was 92.96%, with a NPV value of 98.3%. Conclusion Total serum Ca2+ and Mg2+ levels decrease from the second to third trimesters of pregnancy. A total serum Mg2+ level of > 1.9 mg/dL at 20–28 weeks of gestation is a relatively inexpensive screening tool that can fairly predict preeclampsia later in pregnancy.

  • Open Access

    The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries

    by Who Action Trials Collaborators, Temitope Adesiji Adegboyega, Ebunoluwa Aderonke Adejuyigbe, Olubukola Adeponle Adesina, Babalola Adeyemi, Salahuddin Ahmed, Francis Akinkunmi, Jalemba Aluvaala, Henry Anyabolu, Shabina Ariff, et al.

    Background: Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods: WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion: This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration: ISRCTN11434567. Registered on 7 June 2021.


  • Prerenal Acute Kidney Injury is Still the Most Important Cause for Dialysis in an Obstetric Critical Care Referral Unit of North India: A 3 Year Retrospective Study

    by Jyotsna Suri, Ankita Jain, Rajesh Kumar, Rekha Bharti, Pratima Mittal

    Introduction Pregnancy-related acute kidney injury (PRAKI) causes substantial maternofoetal health burden in developing countries. The causes of PRAKI are diverse, important ones being haemorrhage, sepsis and preeclampsia in developing countries. Methods A retrospective study was conducted in the department of Obstetrics and Gynaecology, and Nephrology in an Indian tertiary care hospital from 2017 to 2019. All patients admitted to Obstetric Critical Care Unit (CCU-Obs) who were pregnant or less than 42 days postpartum, with acute kidney injury and required haemodialysis were enrolled in the study and analysed for risk factors and causes of PRAKI. Results PRAKI occurred in 6.21% admissions in CCU-Obs and 37.42% of these patients required dialysis. Majority were unbooked (85.9%) and referred (65.6%) from other hospitals; 57.8% patients developed AKI postnatally. The main causes for AKI in the current study were prerenal causes (84.4%) like obstetric haemorrhage due to placental abruption and post-partum haemorrhage. Other important causes were severe preeclampsia (23.4%) and sepsis (39%). Many patients had more than one condition leading to AKI. Patients needed 4.98 (average) cycles of dialysis and the average duration of stay in the hospital was 16.89 days. Maternal mortality was seen in a third of the cases, owing to complications of AKI. Preterm delivery was seen in 44%; stillbirth in half the cases and neonatal deaths in a quarter of them. Conclusion To conclude, the leading causes of PRAKI requiring dialysis were obstetric haemorrhage, sepsis and preeclampsia. Prompt management and timely referral to a higher institute will decrease the incidence of PRAKI and its complications.


  • Open Access

    Carle’s obstetric early warning score as a screening tool for critical care admission

    by Chhavi Gupta, Jyotsna Suri, Sumitra Bachani, Rekha Bharti, Divya Pandey, Pratima Mittal

    Background & objectives: Early warning systems (EWS) involve serial observations (track) with criteria (trigger) to timely identify patients at risk of complications. Carle designed a statistically based clinically modified obstetric early warning score (Carle’s OEWS). This study evaluated Carle’s OEWS and its individual components for predicting admission to the obstetric critical care unit (OCCU). Maternal near-miss and maternal mortality were the secondary outcomes. Methods: A prospective observational study was conducted among 1250 pregnant women with a period of gestation ≥28 week admitted in the labour wards of a tertiary centre over 18 months. The physiological parameters of OEWS were recorded and aggregate score was calculated at admission and at regular intervals thereafter, till discharge or OCCU admission. Results: The area under receiver operating characteristic (ROC) curve of OEWS was 0.975 for predicting OCCU admission, 0.971 for near-miss, and 0.996 for predicting maternal mortality and was significant for all outcomes. All individual parameters, except diastolic blood pressure, had a significant relative risk for predicting OCCU requirement. Interpretation & conclusions: Carle’s OEWS is a useful screening tool for predicting obstetric OCCU admission and can be routinely used in labour wards to ensure timely intervention.


  • Prediction of complications of pre‐eclampsia using the fullPIERS high risk predictive model

    by Astha Sharma, Jyotsna Suri, Zeba Khanam, Divya Pandey, Sumitra Bachani, Anuradha Sharma

    Objective: To determine the predicted probability percentage of complications in women with pre‐eclampsia using the Pre‐eclampsia Integrated Estimate of Risk (fullPIERS) model within the first 24 h after admission and assess the model's predictive value for complications of pre‐eclampsia.Methods: This was a prospective cohort study in which the fullPIERS model was applied to 256 pregnant women with pre‐eclampsia within the first 24 h after admission. These women were then followed for 48 h to 7 days for maternal and fetal complications. Reciever operating characteristics (ROC) curves were generated to assess the performance of the fullPIERS model for adverse outcomes of pre‐eclampsia.Results: Of the 256 women enrolled in the study, 101 women (39.5%) developed maternal complications, 120 women (46.9%) developed fetal complications, and 159 women (62.1%) developed both. With an area under the ROC curve of 0.843 (95% confidence interval 0.789–0.897), the fullPIERS model had good discriminating ability to predict complications at any time point between 48 h and 7 days after admission. The sensitivity and specificity of the model at a ≥5.9% cut‐off value for predicting adverse maternal outcomes were 60% and 97%, respectively; they were 44% and 96%, respectively, for predicting combined fetomaternal complications with a cut‐off value of 4.9%.Conclusions: The fullPIERS model performs reasonably well in predicting adverse maternal and fetal outcomes in women with pre‐eclampsia.


  • Comparison of Diabetes in Pregnancy Study Group India (DIPSI) and WHO criteria for diagnosis of gestational diabetes by assessment of fetomaternal outcomes

    by Mansvi Raghav, Jyotsna Suri, Anita Rani, Pradeep Debata, Sumitra Bachani

    ObjectiveTo evaluate fetomaternal outcomes in women who are normoglycemic by Diabetes in Pregnancy Study Group India (DIPSI) but have gestational diabetes mellitus (GDM) by WHO criteria versus those who are normoglycemic by both DIPSI and WHO criteria. MethodsThis was a prospective, cohort study. A total of 635 women participated. They underwent a 2-h non-fasting oral glucose tolerance test (OGTT) and results were interpreted by DIPSI. Out of 635 women, 52 were lost to follow up and 33 were diagnosed as GDM by DIPSI and excluded from the study. The remaining 550 women, after 72 h from the first test, underwent a 75-g fasting-OGTT and results were interpreted using WHO 2013 criteria. Results of the second test were blinded till delivery. The 550 women were followed for fetomaternal outcomes. Participants with normal DIPSI and normal WHO 2013 OGTT were labeled group 1. Participants with normal DIPSI but abnormal WHO 2013 OGTT were labeled group 2. Fetomaternal outcomes were compared between these groups. ResultsOccurrence of GDM by DIPSI was 5.1%, by WHO 2013 criteria it was 10.5%. Composite fetomaternal outcomes occurred more commonly in women with a normal DIPSI but an abnormal WHO 2013 test. Out of 550 women, 492 had normal DIPSI and normal WHO 2013 test. Out of this 492, 116 (23.6%) women had adverse fetomaternal outcomes. Fifty-eight women out of 550 had a normal DIPSI but an abnormal WHO 2013 test. Thirty-seven (63.8%) women out of 58 had adverse fetomaternal outcomes. We found statistically significant association between adverse fetomaternal outcome and GDM by WHO 2013 test (with normal DIPSI test). ConclusionWHO 2013 has superior diagnostic value compared with DIPSI criteria for diagnosis of GDM.


  • Open Access

    Liver transaminase enzyme analysis as a predictor of poor maternal outcome in pregnant women with dengue

    by Megha Panwar, Rekha Bharti, Anjali Dabral, Anita Kumar, Jyotsana Suri, Lovely Singh

    Liver transaminase enzyme analysis as a predictor of poor maternal outcome in pregnant women with dengue - IJOGR- Print ISSN No: - 2394-2746 Online ISSN No:- 2394-2754 Article DOI No:- 10.18231/j.ijogr.2023.009, Indian Journal of Obstetrics and Gynecology Research-Indian J Obstet Gynecol Res